Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Conba Pharmaceutical CoSHSE:600572 +2.61%71 Pretax Margin % is 13.07% as of Mar. 2026, which is 12% above its 10-year median of 11.69. GuruFocus rates SHSE:600572 with a GF Score™ of 71/100 and a GF Value™ of ¥5.51 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Zhejiang Conba Pharmaceutical Co ranks better than 58.65% on this metric.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
SHSE:600572'
s Pretax Margin % Range Over the Past 10 Years
Min: -0.74 Med: 11.69 Max: 38.47
Current: 10
SHSE:600572's Pretax Margin % is ranked better than 58.65% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs SHSE:600572: 10.00
Zhejiang Conba Pharmaceutical Co (SHSE:600572) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Zhejiang Conba Pharmaceutical Co Pretax Margin % Related Terms
Zhejiang Conba Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co Pretax Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Pretax Margin % of 13.07% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is 12% above median its historical median of 11.69. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #397 out of 960 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Zhejiang Conba Pharmaceutical Co's Pretax Margin % too high?
Zhejiang Conba Pharmaceutical Co's current Pretax Margin % of 13.07% is 12% above median its 10-year median of 11.69. The Drug Manufacturers industry median Pretax Margin % is 7.28. Zhejiang Conba Pharmaceutical Co's value of 13.07% is 79.5% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #397 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #397 out of 960 companies for Pretax Margin %. This puts Zhejiang Conba Pharmaceutical Co in the upper half of its industry. The industry median Pretax Margin % is 7.28. Zhejiang Conba Pharmaceutical Co's value of 13.07% is 79.5% above this benchmark. While the company's 10-year median is 11.69 vs. the industry median of 7.28, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current Pretax Margin % of 13.07% is 79.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current Pretax Margin % is 13.07%, which is 12% above median its own 10-year median of 11.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current Pretax Margin % is 13.07%, which is 12% above median its 10-year median of 11.69 and 79.5% above the Drug Manufacturers industry median of 7.28. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Pretax Margin % is 13.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
Pretax Margin %: 13.07% (12% above median its 10-year median of 11.69)
GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
Industry Position: 79.5% above the Drug Manufacturers median (#397 of 960)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Business Description
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score
Get the complete analysis for SHSE:600572
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
